CDER drafts drug de­vel­op­ment guid­ance on NASH with com­pen­sat­ed cir­rho­sis

Last week
R&D

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

Last week
Pharma

Once picked as a $500M win­ner, bank­rupt Achao­gen auc­tions off its an­tibi­ot­ic for a frac­tion of that

Last week
Pharma

Sanofi re­cruits No­var­tis' top phar­ma ex­ec Paul Hud­son as its new CEO — so what hap­pens now?

Last week
People

R&D leader Ver­tex ex­e­cutes a $420M cash gam­bit to dom­i­nate gene edit­ing field for Duchenne MD

Last week
Cell/Gene Tx
Deals

Ex-Juno chief Hans Bish­op takes the helm at can­cer test­ing start­up Grail in a shake­up as IPO ru­mors per­co­late

Last week
People

Vivek Ra­maswamy re­cruits Eli Lil­ly R&D vet Salz­mann as new CEO; Ax­o­vant drops col­lab­o­ra­tion

Last week
Protocols

Pro­tal­ix, Chiesi fire up ac­cel­er­at­ed ap­proval pitch for Fab­ry dis­ease treat­ment

Last week

Fi­nan­cial­ly wob­bly opi­oid drug­mak­er In­sys agrees to pay $225M to set­tle gov­ern­ment probes

Last week
Pharma

Cel­gene can breathe a sigh of re­lief as FDA ac­cepts once-spurned ozan­i­mod ap­pli­ca­tion — set­ting a tar­get date on a block­buster de­ci­sion

Last week
Pharma

As­traZeneca stocks up on Calquence am­mu­ni­tion for big BTK ri­val­ry with J&J, Ab­b­Vie

Last week
R&D

In a blow to sci­ence, Trump ad­min­is­tra­tion aborts fed­er­al fund­ing for fe­tal tis­sue re­search

Last week
R&D

The FDA is forc­ing a small an­tibi­ot­ic play­er back to the clin­ic for a new tri­al — 10 years af­ter first re­jec­tion

Last week
Pharma
R&D

Third Rock rais­es a record $770M to back its own brand of biotech star­tups — while 1 key part­ner ex­its

Last week
Startups

Take­da suf­fers an­oth­er set­back in its quest to ex­pand myelo­ma drug’s reach — and block­buster po­ten­tial

Last week

Pfiz­er scoops Cal­i­co ex­ec Jeff Set­tle­man to head big on­col­o­gy R&D ops in La Jol­la

Last week

For­eign threats to NIH re­search: Sen­ate Fi­nance Com­mit­tee digs in

Last week
China

Clock starts tick­ing on Leif Jo­hansson's re­tire­ment from As­traZeneca chair­man role — re­port

Last week
People

Deer­field strikes up new deal with Co­lum­bia Uni­ver­si­ty; Ovid CEO Je­re­my Levin joins BIO as new board chair

Last week
Protocols

Ned Sharp­less weighs in on gene ther­a­py pric­ing de­bate, sug­gest­ing 'the mes­sag­ing got lost'

Last week
Cell/Gene Tx
People

Mid-stage da­ta on Al­lena's hy­per­ox­aluria drug fu­el op­ti­mism ahead of piv­otal read­out

Last week
R&D

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

Last week
Pharma
R&D

Bris­tol-My­ers bumps off chief sci­en­tist in an­oth­er big shake­up, bring­ing in Cel­gene and No­var­tis ex­ecs

Last week
People
Pharma

Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

Last week
R&D
First page Previous page 123456 Next page Last page